Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) FCF Margin (2016 - 2022)

RedHill Biopharma has reported FCF Margin over the past 11 years, most recently at 18.92% for Q4 2022.

  • Quarterly FCF Margin rose 4839.0% to 18.92% in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 23.58% through Jun 2023, up 4886.0% year-over-year, with the annual reading at 2512.59% for FY2025, 240161.0% down from the prior year.
  • FCF Margin was 18.92% for Q4 2022 at RedHill Biopharma, up from 34.22% in the prior quarter.
  • Over five years, FCF Margin peaked at 18.92% in Q4 2022 and troughed at 983.14% in Q1 2020.
  • The 5-year median for FCF Margin is 88.72% (2021), against an average of 297.97%.
  • Year-over-year, FCF Margin soared 163564bps in 2018 and then tumbled -54981bps in 2020.
  • A 5-year view of FCF Margin shows it stood at 602.58% in 2018, then tumbled by -44bps to 870.19% in 2019, then soared by 93bps to 58.97% in 2020, then dropped by -14bps to 67.31% in 2021, then surged by 72bps to 18.92% in 2022.
  • Per Business Quant, the three most recent readings for RDHL's FCF Margin are 18.92% (Q4 2022), 34.22% (Q3 2022), and 89.49% (Q2 2022).